YahooAugust 11, 2026 at 12:22 PM NY24 days ago

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Companies in This Story